Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPAH-trial: Dapagliflozin in Pulmonary Arterial Hypertension
NCT05179356Phase 2Completed
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapagliflozin in pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH). Started Jan 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT05179356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179356.